Compare SY & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SY | NGEN |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.8M | 317.6M |
| IPO Year | 2018 | N/A |
| Metric | SY | NGEN |
|---|---|---|
| Price | $3.15 | $3.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 340.6K | 101.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.36 | N/A |
| Revenue Next Year | $57.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.67 | $3.55 |
| 52 Week High | $6.28 | $5.93 |
| Indicator | SY | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 45.04 |
| Support Level | $2.80 | $3.69 |
| Resistance Level | $3.33 | $4.44 |
| Average True Range (ATR) | 0.17 | 0.28 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 63.33 | 51.79 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.